Association of Potentially Inappropriate Medication Classes with Mortality Risk Among Older Adults Initiating Hemodialysis.
Association of Potentially Inappropriate Medication Classes with Mortality Risk Among Older Adults Initiating Hemodialysis.
复制标题
DOI：
10.1007/s40266-023-01039-z
复制
发表时间：
2023-08
期刊：
影响因子：
2.8
通讯作者：
McAdams-DeMarco, Mara
中科院分区：
文献类型：
--
作者：
Hall, Rasheeda K.;Muzaale, Abimereki D.;Bae, Sunjae;Steal, Stella M.;Rosman, Lori M.;Segev, Dorry L.;McAdams-DeMarco, Mara
Older adults initiating dialysis have high risk of mortality and that risk may be related to potentially inappropriate medications (PIMs). Our objective was to identify and validate mortality risk associated with American Geriatrics Society Beers Criteria PIM classes and concomitant PIM use. We used United States Renal Data System data to establish a cohort of adults aged ≥65 years initiating dialysis (2013–2014) and had no PIM prescriptions in the six months prior to dialysis initiation. In a development cohort (40% sample), adjusted Cox proportional hazards models were performed to determine which of 30 PIM classes were associated with mortality (or “high risk” PIMs). Adjusted Cox models were performed to assess association of number of “high risk” PIM fills/month with mortality. All models were repeated in the validation cohort (60% sample). In the development cohort (n=15,570), only 13 of 30 PIM classes were associated with higher mortality risk. Compared to those with no “high risk” PIM fills/month, patients having one “high risk” PIM fill/month had 1.29-fold (95% confidence interval [CI], 1.21–1.38) increased risk of death; those with two or more “high risk” PIM fills/month had 1.40-fold (95% CI:1.24–1.58) increased risk. These findings were similar in the validation cohort (n=23,569). Only a minority of Beers Criteria PIM classes may be associated with mortality in the older dialysis population; however, mortality risk increases with concomitant use of “high risk” PIMs. Additional studies are needed to confirm these associations and their underlying mechanisms.
登录
查看更多内容
影响因子：
4.2
作者：
Paik JM;Zhuo M;York C;Tsacogianis T;Kim SC;Desai RJ
通讯作者：
Desai RJ
影响因子：
4.6
作者：
van Oosten MJM;Logtenberg SJJ;Hemmelder MH;Leegte MJH;Bilo HJG;Jager KJ;Stel VS
通讯作者：
Stel VS
影响因子：
2.8
作者：
Pugh MJ;Marcum ZA;Copeland LA;Mortensen EM;Zeber JE;Noël PH;Berlowitz DR;Downs JR;Good CB;Alvarez C;Amuan ME;Hanlon JT
通讯作者：
Hanlon JT
影响因子：
13.6
作者：
Kimmel, Paul L.;Fwu, Chyng-Wen;Eggers, Paul W.
通讯作者：
Eggers, Paul W.
DOI：
10.1053/j.ajkd.2021.03.019
发表时间：
2021-12
期刊：
American journal of kidney diseases : the official journal of the National Kidney Foundation
影响因子：
--
作者：
Hall RK;Blumenthal JB;Doerfler RM;Chen J;Diamantidis CJ;Jaar BG;Kusek JW;Kallem K;Leonard MB;Navaneethan SD;Sha D;Sondheimer JH;Wagner LA;Yang W;Zhan M;Fink JC;CRIC Study Investigators
通讯作者：
CRIC Study Investigators